BRPI1012971A2 - proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central - Google Patents

proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Info

Publication number
BRPI1012971A2
BRPI1012971A2 BRPI1012971A BRPI1012971A BRPI1012971A2 BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2 BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2
Authority
BR
Brazil
Prior art keywords
gdnf
bdnf
application
nervous system
fusion proteins
Prior art date
Application number
BRPI1012971A
Other languages
English (en)
Portuguese (pt)
Inventor
Boivin Dominique
Castaigne Jean-Paul
Demeule Michel
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of BRPI1012971A2 publication Critical patent/BRPI1012971A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1012971A 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central BRPI1012971A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18624609P 2009-06-11 2009-06-11
PCT/CA2010/000889 WO2010142035A1 (en) 2009-06-11 2010-06-11 Fusion proteins for delivery of gdnf and bdnf to the central nervous system

Publications (1)

Publication Number Publication Date
BRPI1012971A2 true BRPI1012971A2 (pt) 2018-01-16

Family

ID=43308346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012971A BRPI1012971A2 (pt) 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Country Status (9)

Country Link
US (1) US20120196803A1 (OSRAM)
EP (1) EP2440581A4 (OSRAM)
JP (1) JP2012529272A (OSRAM)
CN (2) CN102459348A (OSRAM)
AU (1) AU2010258052A1 (OSRAM)
BR (1) BRPI1012971A2 (OSRAM)
CA (1) CA2764777A1 (OSRAM)
MX (1) MX2011013258A (OSRAM)
WO (1) WO2010142035A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US8487072B2 (en) 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
CA2803646A1 (en) * 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CN109996556A (zh) 2016-05-13 2019-07-09 分子医学研究院 治疗与ilc3细胞相关之疾病的方法
CN110461880A (zh) * 2016-11-10 2019-11-15 科乐斯疗法公司 Gdnf融合多肽及其使用方法
CN107141354A (zh) * 2017-05-05 2017-09-08 李斯文 一种融合蛋白及光敏剂复合物及其制备方法和应用
CN114729324A (zh) * 2019-07-24 2022-07-08 斯比根公司 永生化干细胞株的制备方法及其用途
CA3222177A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN116270429B (zh) * 2023-02-17 2025-06-10 山东省药学科学院 一种鼻黏膜给药的抗抑郁制剂及其制备方法和应用
CN120077136A (zh) * 2023-09-28 2025-05-30 广州必贝特医药股份有限公司 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PT2360258E (pt) * 2005-02-18 2015-01-13 Angiochem Inc Moléculas para transportar um composto através da barreira hematoencefálica
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
PL2164866T3 (pl) * 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
US8802631B2 (en) * 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) * 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns

Also Published As

Publication number Publication date
CN103819564A (zh) 2014-05-28
WO2010142035A1 (en) 2010-12-16
MX2011013258A (es) 2012-02-28
AU2010258052A1 (en) 2012-01-12
EP2440581A4 (en) 2013-03-27
US20120196803A1 (en) 2012-08-02
CN102459348A (zh) 2012-05-16
JP2012529272A (ja) 2012-11-22
EP2440581A1 (en) 2012-04-18
CA2764777A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
BRPI1012971A2 (pt) proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central
BRPI1007004A2 (pt) sistema de iluminação, e, aparelho de estereolitografia
BRPI0913526A2 (pt) sistema de aquecimento
EE01079U1 (et) Territooriumi ja selle perimeetri j„lgimise ssteem
BRPI1006922A2 (pt) sistema para descarte de medicação
BRPI0912144A2 (pt) configuração de sistema de infusão
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
BRPI1012304A2 (pt) sistema para auxílio de subida
BRPI0917867A2 (pt) método e sistema para formar estruturas reticuladas de compósito de suporte
ES2864688T8 (es) Sistema de ablación
LT2414015T (lt) Laringoskopas ir sistema
BR112012016186A2 (pt) sistema de recorte para preparar fusão sacroilíaca
BRPI1009247A2 (pt) sistema de comando de aeronave, e, aeronave
BR112012002092A2 (pt) sistema de dessalinização e metodo de dessalinização
BR112015006428A2 (pt) sistema aperfeiçoados de registro de rolos e estruturas associadas
BR112013010183A2 (pt) sistema e método para soldador com funcionalidade de solicitação de ajuda
BR112012000444A2 (pt) sistema de dessalinização e método de dessalinização
BR112013012346A2 (pt) sistema de filtração
BRPI0814521A2 (pt) Sistema de desidratação e método de desidratação
BRPI0820008A2 (pt) Sistema e método para produção de grânulos
BRPI0919749A2 (pt) método para embalagem de cigarro e sistema de embalagem de cigarro
BRPI0911586A2 (pt) sistema e método de broadcast supereconômico
BR112013033525A2 (pt) sistema e método de aquecedor flashline
IT1398480B1 (it) Sistema microfluidico
BRPI1009607A2 (pt) dispositivo de iluminação, dispositivo de conexão e sistema de iluminação

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 17/00 (2006.01), A61K 38/16 (2006.0

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]